EQS-Adhoc: APONTIS PHARMA and Zentiva enter into investment agreement – Zentiva will launch a voluntary public purchase offer
EQS-Ad-hoc: APONTIS PHARMA AG / Key word(s): Tender Offer Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014 APONTIS PHARMA and Zentiva enter into investment agreement – Zentiva will launch a voluntary public purchase offer The offer document (“Offer Document”) will be published on the internet at www.zentiva-offer.com. Since APONTIS PHARMA is not listed on the regulated market, the Offer is not subject to the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz - WpÜG). The Offer will be subject to customary conditions, such as the granting of regulatory approvals. It will also include a minimum acceptance threshold of 65% of all Shares. Zentiva has already secured a stake of approximately 37.5% of the Shares by entering into a share sale and purchase agreement with the main shareholder of APONTIS PHARMA. The Executive Board and the Supervisory Board of APONTIS PHARMA welcome and support the Offer, subject to their review of the Offer Document and in compliance with their fiduciary duties. The members of the Executive Board and Supervisory Board intend to tender all Shares held by them. In accordance with the investment agreement, APONTIS PHARMA will – subject to all fiduciary duties of the Executive Board – apply for the cancellation of the inclusion of the Shares in over-the-counter (OTC) trading on all stock exchanges on which the Shares are traded. Investor Relations CROSS ALLIANCE communication GmbH The information contained in this press release may include certain forward-looking statements that are based on current assumptions and forecasts made by the management of APONTIS PHARMA AG. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Such factors include those discussed in APONTIS PHARMA AG's public reports. These reports are available on www.apontis-pharma.de. The Company assumes no obligation to update such forward-looking statements or to adapt them to future events or developments. End of Inside Information
16-Oct-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | APONTIS PHARMA AG |
Rolf-Schwarz-Schütte-Platz 1 | |
40789 Monheim am Rhein | |
Germany | |
E-mail: | ir@apontis-pharma.de |
Internet: | https://apontis-pharma.de/ |
ISIN: | DE000A3CMGM5 |
WKN: | A3CMGM |
Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 2009155 |
End of Announcement | EQS News Service |
|
2009155 16-Oct-2024 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
The most important financial data at a glance | ||||||||
2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | ||
Sales1 | 44,80 | 40,04 | 39,24 | 51,18 | 55,73 | 36,96 | 48,70 | |
EBITDA1,2 | 2,81 | -1,72 | 1,00 | 2,36 | 5,57 | -13,28 | 3,30 | |
EBITDA-Margin3 | 6,27 | -4,30 | 2,55 | 4,61 | 10,00 | -35,93 | 6,78 | |
EBIT1,4 | 2,50 | -2,29 | -0,66 | 0,62 | 3,77 | -15,16 | 1,30 | |
EBIT-Margin5 | 5,58 | -5,72 | -1,68 | 1,21 | 6,77 | -41,02 | 2,67 | |
Net Profit (Loss)1 | 2,37 | -2,39 | -1,18 | -0,75 | 2,69 | -12,68 | 1,00 | |
Net-Margin6 | 5,29 | -5,97 | -3,01 | -1,47 | 4,83 | -34,31 | 2,05 | |
Cashflow1,7 | 4,46 | -0,24 | 1,45 | 3,43 | 11,02 | -12,60 | 0,00 | |
Earnings per share8 | 0,28 | -0,28 | -0,14 | -0,09 | 0,32 | -1,49 | 0,12 | |
Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: RSM Ebner Stolz
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
INVESTOR-INFORMATION | ||||||
©boersengefluester.de | ||||||
Apontis Pharma | ||||||
WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
A3CMGM | DE000A3CMGM5 | AG | 85,85 Mio € | 11.05.2021 | Verkaufen | 9F383VCV+FH |
PE 2025e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
27,30 | 25,63 | 1,07 | 53,44 | 2,84 | -6,82 | 2,32 |
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
0,00 | 0,00 | 0,00 | 0,00% |
Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
17.05.2024 | 08.05.2024 | 09.08.2024 | 07.11.2024 | 28.03.2024 |
Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
+10,36% | +22,16% | +112,63% | +117,67% | -46,84% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.